These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15972381)

  • 1. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
    Patel K; Hursting MJ
    Am J Health Syst Pharm; 2005 Jul; 62(13):1381-4. PubMed ID: 15972381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
    Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M
    J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
    J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Lazar J; Cavusoglu E
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
    J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
    Kereiakes DJ; Lorenz T; Young JJ; Kukielka G; Mueller MN; Nanniazzi-Alaimo L; Phillips DR
    J Thromb Thrombolysis; 2001 Oct; 12(2):123-7. PubMed ID: 11729363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 9. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
    Lele M; Sajid M; Wajih N; Stouffer GA
    Circulation; 2001 Jul; 104(5):582-7. PubMed ID: 11479257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K
    Herz; 2001 Apr; 26 Suppl 1():30-5. PubMed ID: 11349624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
    Magee AN; Hogan DF; Sederquist KA; Durham JA
    Am J Vet Res; 2014 Mar; 75(3):309-12. PubMed ID: 24564318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
    Bergquist PA; Hunke WA; Reed RA; Manas D; Forsyth RJ; Kenney RR; Cook J; Holahan M
    J Clin Pharm Ther; 1999 Apr; 24(2):125-32. PubMed ID: 10380064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
    King S; Short M; Harmon C
    Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
    Untch B; Ahmad S; Messmore HL; Schultz CL; Ma Q; Hoppensteadt DA; Walenga JM; Fareed J
    Thromb Res; 2002 Apr; 106(2):149-56. PubMed ID: 12182915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.
    Lang SH; Manning N; Armstrong N; Misso K; Allen A; Di Nisio M; Kleijnen J
    Curr Med Res Opin; 2012 Mar; 28(3):351-70. PubMed ID: 22292469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
    Bergquist PA; Manas D; Hunke WA; Reed RA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1218-23. PubMed ID: 11449879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S; Tamura N; Ishida H
    J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
    Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
    J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.